** IMPORTANT MESSAGE ABOUT RESEARCH AT UCLH DURING THE COVID-19 OUTBREAK**
** FROM PROFESSOR BRYAN WILLIAMS, UCLH RESEARCH DIRECTOR AND BRC DIRECTOR & DR NICK McNALLY, MANAGING DIRECTOR, RESEARCH UCLH/UCL **
COVID-19 procedures are in place for researchers at UCLH.
Read the full statement from UCLH R&D plus the guidance from the HRA and MHRA.
This is a rapidly evolving situation and we will post updates to this guidance on the JRO news page.
Please consider the advice below after reading the full UCLH statement.
Principal Investigators should also alert their sponsors to the UCLH R&D statement – and keep them informed of any updates to UCLH guidance.
Studies active at UCLH:
Where sponsors and Principal Investigators have determined a study falls into the priority research categories identified within the UCLH statement, they should email uclh.randd@nhs.net marking their email with “COVID-19 Continuation of Recruitment” providing details of the study: its title, identifier, sponsor and the rationale for continuing recruitment.
Should your study require pharmacy support, you should alert the UCLH pharmacy to the fact that recruitment will continue, and discuss your requirements directly with them.
Studies not yet active at UCLH:
The Joint Research Office, Clinical Research Facility and Cancer Clinical Trials Unit will continue to review your study but will not issue Decisions to Deliver. Please discuss with sponsors as soon as possible.
Remote monitoring
Where sponsors and Principal Investigators determine a need to request remote access for monitors (in line with the guidance from the HRA, MHRA and UCLH), they should firstly consult the COVID-19 – UCLH Remote Monitoring Arrangements guidance document. Any questions regarding monitoring should be directed to research-incidents@ucl.ac.uk (EpicCare Link specific queries can be directed to uclh.ehrs.researchstudies@nhs.net).
UCL and UCLH sponsored studies
If your study is sponsored by UCL or UCLH please also review the guidance we issued on Friday 13 March.
